Issues related to development of new antiseizure treatments

• This report represents a summary of the discussions led by the antiseizure treatment working group of the International League Against Epilepsy (ILAE)/American Epilepsy Society (AES) Working Groups joint meeting in London (London Meeting). Wereview here what is currently known about the pharmacologic characteristics of current models of refractory seizures, both for adult and pediatric epilepsy. In addition, we address how the National Institute of Neurological Disorders and Stroke (NINDS)-funded Anticonvulsant Screening Program (ASP) is evolving to incorporate appropriate animal models in the search for molecules that might be sufficiently novel to warrant further pharmacologic development. Wealso briefly address what we believe is necessary, going forward, to achieve the goal of stopping seizures in all patients, with a call to arms for funding agencies, the pharmaceutical industry, and basic researchers.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine (hsv//eng)

Nyckelord

Antiseizure drug

Pharmacoresistant epilepsy

Animal models of epilepsy

temporal-lobe epilepsy

resistant kindled rats

spontaneous recurrent

seizures

anticonvulsant screening-program

kainate-induced epilepsy

phenytoin-resistant

antiepileptic drugs

mouse model

status

epilepticus

pharmacological characterization

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)